Phase II clinical trial of tetrathiomolybdate was conducted in patients with breast cancer, for which it was hypothesized that copper depletion would result in a reduction of VEGFR2-positive endothelial progenitor cells, alterations to the tumor microenvironment and improvements in event-free and overall survival [71]. Here, KDR is linked to breast carcinoma.